These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 30305172)

  • 1. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
    Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC
    J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis outcomes after cancer immunotherapy.
    Garcia CR; Jayswal R; Adams V; Anthony LB; Villano JL
    Clin Transl Oncol; 2019 Oct; 21(10):1336-1342. PubMed ID: 30788836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy-associated autoimmune hemolytic anemia.
    Khan U; Ali F; Khurram MS; Zaka A; Hadid T
    J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
    Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
    Sukari A; Nagasaka M; Alhasan R; Patel D; Wozniak A; Ramchandren R; Vaishampayan U; Weise A; Flaherty L; Jang H; Kim S; Gadgeel S
    Anticancer Res; 2019 Feb; 39(2):781-790. PubMed ID: 30711957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma.
    Trinh B; Sanchez GO; Herzig P; Läubli H
    J Immunother Cancer; 2019 Feb; 7(1):52. PubMed ID: 30791949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
    Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
    Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
    Diab A; Tannir NM; Bentebibel SE; Hwu P; Papadimitrakopoulou V; Haymaker C; Kluger HM; Gettinger SN; Sznol M; Tykodi SS; Curti BD; Tagliaferri MA; Zalevsky J; Hannah AL; Hoch U; Aung S; Fanton C; Rizwan A; Iacucci E; Liao Y; Bernatchez C; Hurwitz ME; Cho DC
    Cancer Discov; 2020 Aug; 10(8):1158-1173. PubMed ID: 32439653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors.
    Rapisuwon S; Izar B; Batenchuk C; Avila A; Mei S; Sorger P; Parks JM; Cooper SJ; Wagner D; Zeck JC; Charabaty AJ; Atkins MB
    J Immunother Cancer; 2019 Mar; 7(1):61. PubMed ID: 30832716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
    Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
    J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors.
    Firwana B; Ravilla R; Raval M; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Dec; 23(8):620-624. PubMed ID: 27590328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer].
    Jacquin-Porretaz C; Nardin C; Puzenat E; Roche-Kubler B; Aubin F;
    Presse Med; 2017 Sep; 46(9):808-817. PubMed ID: 28683958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
    Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
    J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.
    Liu RC; Consuegra G; Chou S; Fernandez Peñas P
    Clin Exp Dermatol; 2019 Aug; 44(6):643-646. PubMed ID: 30618056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
    Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.